Posters
« Back
ADP-Glo™ Kinase Profiling Systems for Targeted and Flexible Kinase Inhibitor Profiling
EP23511
Poster Title: ADP-Glo™ Kinase Profiling Systems for Targeted and Flexible Kinase Inhibitor Profiling
Submitted on 09 Oct 2015
Author(s): Hicham Zegzouti, Jacquelyn Hennek, Juliano Alves, and Said Goueli
Affiliations: Promega Corporation
Poster Views: 2,184
View poster »


Poster Information
Abstract: Drug safety is of paramount importance in the pharmaceutical industry indicating that minimal side effects constitute a major requirement in drug development. Therefore, novel drug candidates need to be profiled against various liability targets, including a broad panel of kinases to provide a better understanding of off-target activities. Potentially, profiling can also identify new targets that may lead to novel therapeutic indications. A universal, robust and affordable technology is desirable to assess selectivity and potency of drug candidates against multiple classes of kinases. The luminescent ADP-Glo™ kinase assay is a universal platform that measures kinase activity by quantifying the amount of ADP produced during the enzymatic reaction. We have tested the utility of this platform with 174 optimized Kinase Enzyme Systems (KES) spanning different families of the human kinome. Here we present standardized Kinase Profiling Systems for simple kinase inhibitor profiling studies. The Kinase Profiling Systems are a set of kinases organized by families and presented in easy to use multiwell strips. Each strip contains eight enzymes each with their corresponding substrates, and standardized for optimal kinase activity for inhibitor profiling. Using the profiling strips we easily generated selectivity profiles, identifying compound promiscuity towards members of a single kinase subfamily or different subfamilies of the kinome. The ADP-Glo™ KES platforms now address the needs of basic kinase characterization, kinase screening, mode of action (MOA) studies and profiling in an affordable manner using one assay format.Summary: Drug safety is of paramount importance in the pharmaceutical industry indicating that minimal side effects constitute a major requirement in drug development. Therefore, novel drug candidates need to be profiled against various liability targets, including a broad panel of kinases to provide a better understanding of off-target activities. Potentially, profiling can also identify new targets that may lead to novel therapeutic indications.References: Hicham Zegzouti, Jacquelyn Hennek, Juliano Alves, and Said Goueli
Promega Corporation, 2800 Woods Hollow Rd, Madison, WI 53711
Report abuse »
Questions
Ask the author a question about this poster.
Ask a Question »

Creative Commons

Related Posters


The Good, the Bad and the Ugly: Selective single cell isolation
Sandra Lubos1,2, Nils K├Ârber1, Heide Marie Resch1, Iris Augustin2, Stefan Niehren1

Osteolytic jaw lesions
Dr. Amal Hassan Zakarya, Sarah Ahmed Mohamed, Noura Mohamed Kamal, Heba Ahmed Saleh, Ali Abd Elwahed

Evaluation of the Orion Outlier Detection Algorithm for Data Streams
Nam Phung

Influences of the Psychosocial Context of Practice Learning in an Experiential Group Work Course
Mark Cameron and Kathy Pjura

A Novel Enzymatic Assay for Determination of Phosphatidylinositol in Biological Samples
Paul Templeton, Kyle C. Schmitt, Grigoriy Tchaga,and Gordon Yan